Related Experiment Videos
A management trial for Duchenne cardiomyopathy
Y Ishikawa1, J R Bach, Y Ishikawa
1Department of Pediatrics, Sapporo University of Medicine, Hokkaido, Japan.
American Journal of Physical Medicine & Rehabilitation
|September 1, 1995
Summary
Physicians can now prolong survival for individuals with neuromuscular disease. New treatments combining ACE inhibitors and beta-blockers show promise for managing muscular dystrophy-associated cardiomyopathy.
Area of Science:
- Cardiology
- Neurology
- Pulmonology
Background:
- Physiatrists can prolong survival in neuromuscular disease patients using respiratory aids.
- Increased survival leads to higher morbidity and mortality from cardiomyopathy in generalized myopathies.
Purpose of the Study:
- To evaluate the efficacy of novel therapeutic regimens for cardiomyopathy in patients with dystrophin-deficient muscular dystrophy.
Main Methods:
- Retrospective analysis of 100 patients with muscular dystrophy and dilated cardiomyopathy (DCM).
- Evaluation of digitalis and diuretics, followed by the addition of ACE inhibitors (enalapril) and beta-blockers in symptomatic patients.
Main Results:
- Nine of 14 patients with DCM were asymptomatic on digitalis and diuretics, despite low left ventricular ejection fractions (LVEFs).
- Five patients with symptomatic heart failure and severe ventricular dilatation showed improvement with the addition of ACE inhibitors and beta-blockers.
- Two of these five patients died within one year.
Conclusions:
- The combination of ACE inhibitors and beta-blockers may effectively manage muscular dystrophy-associated cardiomyopathy.
- Further research is warranted to explore this combined therapeutic approach for muscular dystrophy-associated cardiomyopathy.